Scalable Multiplexed Drug-Combination Screening Platforms Using 3D Microtumor Model for Precision Medicine.

Cancer heterogeneity is a notorious hallmark of this disease, and it is desirable to tailor effective treatments for each individual patient. Drug combinations have been widely accepted in cancer treatment for better therapeutic efficacy as compared to a single compound. However, experimental complexity and cost grow exponentially with more target compounds under investigation. The primary challenge remains to efficiently perform a large-scale drug combination screening using a small number of patient primary samples for testing. Here, a scalable, easy-to-use, high-throughput drug combination screening scheme is reported, which has the potential of screening all possible pairwise drug combinations for arbitrary number of drugs with multiple logarithmic mixing ratios. A "Christmas tree mixer" structure is introduced to generate a logarithmic concentration mixing ratio between drug pairs, providing a large drug concentration range for screening. A three-layer structure design and special inlets arrangement facilitate simple drug loading process. As a proof of concept, an 8-drug combination chip is implemented, which is capable of screening 172 different treatment conditions over 1032 3D cancer spheroids on a single chip. Using both cancer cell lines and patient-derived cancer cells, effective drug combination screening is demonstrated for precision medicine.

[1]  L. Pusztai,et al.  Cancer heterogeneity: implications for targeted therapeutics , 2013, British Journal of Cancer.

[2]  D. Huh,et al.  Organs-on-chips at the frontiers of drug discovery , 2015, Nature Reviews Drug Discovery.

[3]  John C. Boik,et al.  Quantifying synergism/antagonism using nonlinear mixed‐effects modeling: A simulation study , 2008, Statistics in medicine.

[4]  Deok-Ho Kim,et al.  Microfluidics-assisted in vitro drug screening and carrier production. , 2013, Advanced drug delivery reviews.

[5]  Anna Carbone,et al.  Antagonistic interactions between gemcitabine and 5-fluorouracil in the human pancreatic carcinoma cell line capan-2 , 2006, Cancer biology & therapy.

[6]  A. Jayaraman,et al.  A programmable microfluidic cell array for combinatorial drug screening. , 2012, Lab on a chip.

[7]  Georges Noel,et al.  Three-Dimensional Cell Culture: A Breakthrough in Vivo , 2015, International journal of molecular sciences.

[8]  Thomas M. Gress,et al.  DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma , 2016, BMC Cancer.

[9]  Sangeeta N Bhatia,et al.  Engineering protein and cell adhesivity using PEO-terminated triblock polymers. , 2002, Journal of biomedical materials research.

[10]  Laurie Thomas,et al.  Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer , 2007, Cancer journal.

[11]  R. Shoemaker The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[12]  Ben Lehner Genotype to phenotype: lessons from model organisms for human genetics , 2013, Nature Reviews Genetics.

[13]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[14]  Lackner,et al.  The Role of Next‐Generation Sequencing in Enabling Personalized Oncology Therapy , 2016, Clinical and translational science.

[15]  Y F Hui,et al.  Gemcitabine: a cytidine analogue active against solid tumors. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[16]  D. Yardley,et al.  Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes , 2013, International journal of breast cancer.

[17]  R C Young,et al.  Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer , 1975, Cancer.

[18]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[19]  Sam Michael,et al.  High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells , 2014, Proceedings of the National Academy of Sciences.

[20]  Yong Xu,et al.  Lessons from patient-derived xenografts for better in vitro modeling of human cancer. , 2014, Advanced drug delivery reviews.

[21]  Andrea Sottoriva,et al.  Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine , 2016, Trends in cancer.

[22]  Sam Michael,et al.  A robotic platform for quantitative high-throughput screening. , 2008, Assay and drug development technologies.

[23]  Tao Xu,et al.  Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways , 2013, PLoS Comput. Biol..

[24]  Mickael Guedj,et al.  Analysis of drug combinations: current methodological landscape , 2015, Pharmacology research & perspectives.

[25]  Marilena Loizidou,et al.  3D tumour models: novel in vitro approaches to cancer studies , 2011, Journal of Cell Communication and Signaling.

[26]  A. Lipton,et al.  Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer , 2010, Journal of clinical gastroenterology.

[27]  Julia Schüler,et al.  Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma. , 2014, Urologic oncology.

[28]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[29]  M. Clarke,et al.  Identification of pancreatic cancer stem cells. , 2007, Cancer research.

[30]  N. Mortensen,et al.  Reexamination of Hagen-Poiseuille flow: shape dependence of the hydraulic resistance in microchannels. , 2004, Physical review. E, Statistical, nonlinear, and soft matter physics.

[31]  Paul S Mischel,et al.  A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. , 2013, Carcinogenesis.

[32]  E. V. Van Allen,et al.  Next-generation sequencing to guide cancer therapy , 2015, Genome Medicine.

[33]  Xia Lou,et al.  High-Throughput Cancer Cell Sphere Formation for Characterizing the Efficacy of Photo Dynamic Therapy in 3D Cell Cultures , 2015, Scientific Reports.

[34]  B. Al-Lazikani,et al.  Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance , 2012, Clinical pharmacology and therapeutics.

[35]  Seyed Ali Mousavi Shaegh,et al.  Microfluidics for Advanced Drug Delivery Systems , 2015, Current opinion in chemical engineering.

[36]  Anna Jagusiak,et al.  Molecular Dynamics Study of Cisplatin Release from Carbon Nanotubes Capped by Magnetic Nanoparticles , 2013 .

[37]  S. Loi,et al.  Precision medicine for metastatic breast cancer—limitations and solutions , 2015, Nature Reviews Clinical Oncology.

[38]  Wei Zheng,et al.  Phenotypic screens as a renewed approach for drug discovery. , 2013, Drug discovery today.

[39]  Zhixiong Zhang,et al.  Microfluidics 3D gel-island chip for single cell isolation and lineage-dependent drug responses study. , 2016, Lab on a chip.

[40]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[41]  Ying Zhu,et al.  Cell-based drug combination screening with a microfluidic droplet array system. , 2013, Analytical chemistry.

[42]  Kwangmi Kim,et al.  Microfluidic System Based High Throughput Drug Screening System for Curcumin/TRAIL Combinational Chemotherapy in Human Prostate Cancer PC3 Cells , 2014, Biomolecules & therapeutics.

[43]  Se-Kwon Kim,et al.  Log-scale dose response of inhibitors on a chip. , 2011, Analytical chemistry.

[44]  L. Panasci,et al.  Chemotherapy for advanced pancreatic cancer. A comparison of 5‐fluorouracil, adriamycin, and mitomycin (fam) with 5‐fluorouracil, streptozotocin, and mitomycin (fsm) , 1986, Cancer.

[45]  Zhixiong Zhang,et al.  Single cell dual adherent-suspension co-culture micro-environment for studying tumor-stromal interactions with functionally selected cancer stem-like cells. , 2016, Lab on a chip.

[46]  R. K. Mehmood,et al.  Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibody Treatments , 2014, Oncology reviews.

[47]  John G. Moffat,et al.  Phenotypic screening in cancer drug discovery — past, present and future , 2014, Nature Reviews Drug Discovery.

[48]  B. Chung,et al.  Human neural stem cell growth and differentiation in a gradient-generating microfluidic device. , 2005, Lab on a chip.